zimmer20170501_sc13g.htm

0001437749-17-007644.txt : 20170501 0001437749-17-007644.hdr.sgml : 20170501 20170501170253 ACCESSION NUMBER: 0001437749-17-007644 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170501 DATE AS OF CHANGE: 20170501 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88072 FILM NUMBER: 17801666 BUSINESS ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ZIMMERMAN RONALD CENTRAL INDEX KEY: 0001242026 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 SC 13G 1 zimmer20170501_sc13g.htm SCHEDULE 13G zimmer20170501_sc13g.htm

CUSIP: 25456J104	13G
	1 of 5

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

PLx Pharma Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

25456J104

(CUSIP Number)

April 19, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)

☒	Rule 13d-1(c)

☐	Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

CUSIP: 25456J104	13G
	2 of 5

1	names of reporting persons
	Ronald R. Zimmerman
2	check the appropriate box if a member of a group (A) ☐ (B) ☐
3	sec use only
4	citizenship or place of organization TX
number of shares beneficially owned by each reporting person with		5	sole voting power 377,408
		6	shared voting power 0
		7	sole dispositive power 377,408
		8	shared dispositive power 0
9	aggregate amount beneficially owned by each reporting person
	377,408
10	check box if the aggregate amount in row (9) excludes certain shares ☐
11	percent of class represented by amount in row (9)
	6.1% ⁽¹⁾
12	type of reporting person IN

¹ Based on 6,037,824 shares of Common Stock of PLx Pharma Inc. (f/k/a Dipexium Pharmaceuticals, Inc.) (the “Issuer”) outstanding as of April 19, 2017, as reported by the Issuer in its Form 8-K filed with the Securities and Exchange Commission on April 20, 2017.

CUSIP: 25456J104	13G
	3 of 5

SCHEDULE 13G

Item 1.

(a)

Name of Issuer:

PLx Pharma Inc., a Delaware corporation (the “Issuer”).

(b)

Address of Issuer’s Principal Executive Offices:

8285 El Rio Street

Suite 130

Houston, Texas 77054

Item 2.

(a)

Name of Person Filing:

Robert R. Zimmerman

(b)

Address of Principal Business Office or, if none, Residence:

The address of the principal business office for the Reporting Person is:

8285 El Rio Street

Suite 130

Houston, Texas 77054

(c)

Citizenship:

The Reporting Person is a citizen of the United States of America.

(d)

Title of Class of Securities:

Common Stock, $0.001 par value.

(e)

CUSIP Number:

25456J104.

Item 3.

Not Applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

The Reporting Person may be deemed the beneficial owner of 377,408 shares of Common Stock, which includes 112,509 shares of Common Stock issuable upon exercise of outstanding options.

(b)

Percent of class:

The Reporting Person may be deemed the beneficial owner of 6.1% of the outstanding shares of Common Stock. This percentage was calculated based on the 6,037,824 shares of Common Stock issued and outstanding as of April 19, 2017, as reported in the Issuer’s Form 8-K filed on April 20, 2017 with the Securities and Exchange Commission.

CUSIP: 25456J104	13G
	4 of 5

(c)

Number of shares as to which such person has:

	(i)	Sole power to vote or to direct the vote
		377,408.

	(ii)	Shared power to vote or to direct the vote
		0.

	(iii)	Sole power to dispose or to direct the disposition of
		377,408.

	(iv)	Shared power to dispose or to direct the disposition of
		0.

Item 5.

Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP: 25456J104	13G
	5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 1, 2017

/s/ Ronald R. Zimmerman

Ronald R. Zimmerman